ArticleCancer immunology, immunotherapy : CII2023

HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.

Meiting Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.